MX356699B - Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilme tilamino) quinazolin-2-il]piridin-3-sulfonamida. - Google Patents

Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilme tilamino) quinazolin-2-il]piridin-3-sulfonamida.

Info

Publication number
MX356699B
MX356699B MX2014014525A MX2014014525A MX356699B MX 356699 B MX356699 B MX 356699B MX 2014014525 A MX2014014525 A MX 2014014525A MX 2014014525 A MX2014014525 A MX 2014014525A MX 356699 B MX356699 B MX 356699B
Authority
MX
Mexico
Prior art keywords
ylmethylamino
quinazolin
sulfonamide
pyridin
pyridine
Prior art date
Application number
MX2014014525A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014525A (es
Inventor
S Warrier Jayakumar
Dnyanoba Yadav Navnath
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2014014525A publication Critical patent/MX2014014525A/es
Publication of MX356699B publication Critical patent/MX356699B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014014525A 2012-06-11 2013-06-10 Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilme tilamino) quinazolin-2-il]piridin-3-sulfonamida. MX356699B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (2)

Publication Number Publication Date
MX2014014525A MX2014014525A (es) 2015-02-24
MX356699B true MX356699B (es) 2018-06-11

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014525A MX356699B (es) 2012-06-11 2013-06-10 Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilme tilamino) quinazolin-2-il]piridin-3-sulfonamida.

Country Status (34)

Country Link
US (1) US9238666B2 (enExample)
EP (1) EP2858987B1 (enExample)
JP (1) JP6234450B2 (enExample)
KR (1) KR102092984B1 (enExample)
CN (1) CN104350048B (enExample)
AR (1) AR091402A1 (enExample)
AU (1) AU2013274619B2 (enExample)
BR (1) BR112014030629B1 (enExample)
CA (1) CA2876359C (enExample)
CL (1) CL2014003361A1 (enExample)
CO (1) CO7160032A2 (enExample)
CY (1) CY1120432T1 (enExample)
DK (1) DK2858987T3 (enExample)
EA (1) EA024692B1 (enExample)
ES (1) ES2675314T3 (enExample)
HR (1) HRP20180815T8 (enExample)
HU (1) HUE039210T2 (enExample)
IL (1) IL236074A (enExample)
LT (1) LT2858987T (enExample)
MX (1) MX356699B (enExample)
MY (1) MY169219A (enExample)
NZ (1) NZ703632A (enExample)
PE (1) PE20150228A1 (enExample)
PH (1) PH12014502747B1 (enExample)
PL (1) PL2858987T3 (enExample)
PT (1) PT2858987T (enExample)
RS (1) RS57376B1 (enExample)
SG (1) SG11201408076WA (enExample)
SI (1) SI2858987T1 (enExample)
SM (1) SMT201800369T1 (enExample)
TN (1) TN2014000499A1 (enExample)
TW (1) TWI571470B (enExample)
WO (1) WO2013188254A1 (enExample)
ZA (1) ZA201500161B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9403834B2 (en) * 2013-03-11 2016-08-02 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008366B (zh) * 2013-03-11 2017-11-14 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
KR20180084049A (ko) * 2015-11-19 2018-07-24 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 제약 화합물의 아민 전구약물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP2016516691A (ja) * 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのイソキノリン
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
TW201402592A (zh) 2014-01-16
EP2858987A1 (en) 2015-04-15
PH12014502747A1 (en) 2015-02-02
CN104350048B (zh) 2016-12-07
AR091402A1 (es) 2015-02-04
AU2013274619A1 (en) 2015-01-29
CO7160032A2 (es) 2015-01-15
JP6234450B2 (ja) 2017-11-22
CA2876359A1 (en) 2013-12-19
PH12014502747B1 (en) 2015-02-02
RS57376B1 (sr) 2018-08-31
CN104350048A (zh) 2015-02-11
NZ703632A (en) 2016-01-29
JP2015521598A (ja) 2015-07-30
CY1120432T1 (el) 2019-07-10
BR112014030629A2 (pt) 2017-06-27
WO2013188254A1 (en) 2013-12-19
EA201492256A1 (ru) 2016-05-31
SI2858987T1 (en) 2018-06-29
KR20150023667A (ko) 2015-03-05
PL2858987T3 (pl) 2018-08-31
CL2014003361A1 (es) 2015-05-29
PT2858987T (pt) 2018-07-04
HRP20180815T8 (hr) 2019-02-08
US20150175641A1 (en) 2015-06-25
ZA201500161B (en) 2017-04-26
IL236074A0 (en) 2015-02-01
MY169219A (en) 2019-03-19
SMT201800369T1 (it) 2018-09-13
HRP20180815T1 (hr) 2018-06-29
DK2858987T3 (en) 2018-07-30
HK1203928A1 (en) 2015-11-06
MX2014014525A (es) 2015-02-24
SG11201408076WA (en) 2015-01-29
HUE039210T2 (hu) 2018-12-28
EA024692B1 (ru) 2016-10-31
LT2858987T (lt) 2018-07-10
PE20150228A1 (es) 2015-02-19
AU2013274619B2 (en) 2017-09-28
ES2675314T3 (es) 2018-07-10
TWI571470B (zh) 2017-02-21
KR102092984B1 (ko) 2020-03-24
US9238666B2 (en) 2016-01-19
BR112014030629B1 (pt) 2021-12-21
EP2858987B1 (en) 2018-04-25
IL236074A (en) 2016-08-31
CA2876359C (en) 2020-01-21
TN2014000499A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
AU2012214029A8 (en) Rorgammat inhibitors
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MY160243A (en) Quinazolines as potassium ion channel inhibitors
MY172924A (en) Neprilysin inhibitors
PH12014502733A1 (en) Neprilysin inhibitors
MY165087A (en) Neprilysin inhibitors
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX339873B (es) Inhibidores de serina/treonina cinasa.
MX360679B (es) Derivados de betulina.
HK1215579A1 (zh) 被取代的2,3-二氫苯並呋喃基化合物和其用途
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2013177349A3 (en) Quinazolinediones as tankyrase inhibitors
IN2014CN04449A (enExample)
WO2015042414A8 (en) Multicyclic compounds and methods of using same
PH12014502747A1 (en) Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
PH12013501897A1 (en) Azole derivative
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
HK1231074A1 (en) Neprilysin inhibitors
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production

Legal Events

Date Code Title Description
FG Grant or registration